Enhancer of zeste homolog 2 (EZH2) and SET domain bifurcated 1 (SETDB1, also known as
ESET) are oncogenic methyltransferases implicated in a number of human cancers. These …

The H3K27 histone methyltransferase, Ezh2 (enhancer of zeste 2), is a Polycomb group
protein that plays important roles in many biological processes including cellular …

Epigenetic modifications in cancer stem cells largely result in phenotypic and functional
heterogeneity in many solid tumors. Increasing evidence indicates that enhancer of zeste …

The methyltransferase SETD2 regulates cryptic transcription, alternative splicing, and the
DNA damage response. It is mutated in a variety of cancers and is believed to be a tumor …

Melanoma is a metastatic cancer associated with poor survival. Here, we study a
subpopulation of melanoma cancer cells displaying melanoma cancer stem cell (MCS cells) …

It has been proposed that an aggressive secondary cancer stem cell population arises from
a primary cancer stem cell population through acquisition of additional genetic mutations …

Overexpression of the polycomb group protein enhancer of zeste homologue 2 (EZH2)
occurs in diverse malignancies, including prostate cancer, breast cancer, and glioblastoma …

Accumulated evidence shows that EZH2 is deregulated in a wide range of cancer types, and
it has a crucial role in stem cell maintenance and tumour development. Therefore, blocking …

Polycomb group proteins, including Ezh2, are important candidate stem cell maintenance
proteins in epidermal squamous cell carcinoma. We previously showed that epidermal …

The level of SETD2-mediated H3K36me3 is inversely correlated with that of EZH2-catalyzed
H3K27me3. Nevertheless, it remains unclear whether these two enzymatic activities are …